These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. Biological response modifiers: the new immunotherapy. Foon KA Cancer Res; 1989 Apr; 49(7):1621-39. PubMed ID: 2466558 [No Abstract] [Full Text] [Related]
4. Biologic agents and approaches in the management of patients with lymphoma. A critical appraisal. Longo DL Hematol Oncol Clin North Am; 1991 Oct; 5(5):1067-87. PubMed ID: 1718939 [TBL] [Abstract][Full Text] [Related]
5. Interferons and cytokines. Luger TA Curr Probl Dermatol; 1989; 18():269-76. PubMed ID: 2472932 [No Abstract] [Full Text] [Related]
7. Therapeutic properties of biological response modifiers. A discussion of preclinical and clinical studies. Talmadge JE Contrib Gynecol Obstet; 1989; 17():49-62. PubMed ID: 2495895 [No Abstract] [Full Text] [Related]
8. New therapeutic modalities for cancer. Thomas H; Sikora K Acta Oncol; 1991; 30(1):107-20. PubMed ID: 1706927 [TBL] [Abstract][Full Text] [Related]
9. Biologics as cancer treatment modalities. Smalley RV Wis Med J; 1987 Nov; 86(11):19-21. PubMed ID: 2447705 [No Abstract] [Full Text] [Related]
10. Cytokines in cancer therapy. Parkinson DR Urology; 1989 Oct; 34(4 Suppl):69-74; discussion 87-96. PubMed ID: 2477937 [TBL] [Abstract][Full Text] [Related]
11. Cytokines and immunological monitoring. Sosman JA; Sawhaney A Cancer Chemother Biol Response Modif; 1997; 17():217-86. PubMed ID: 9551216 [No Abstract] [Full Text] [Related]
12. [Monoclonal antibodies and mediators--immunologic tumor therapy]. Baron D Naturwissenschaften; 1990 Sep; 77(9):405-11. PubMed ID: 1701222 [TBL] [Abstract][Full Text] [Related]
13. [Biological response modifiers and cancer treatment]. Urushizaki I Gan No Rinsho; 1989 Jan; Spec No():25-33. PubMed ID: 2464707 [No Abstract] [Full Text] [Related]
14. Overview of advances in the use of biological proteins in human cancer. Gutterman J Semin Oncol; 1988 Oct; 15(5 Suppl 5):2-6. PubMed ID: 2461593 [No Abstract] [Full Text] [Related]
15. New antineoplastic therapies and inherent risks: monoclonal antibodies, biologic response modifiers and interleukin-2. Dillman JB J Intraven Nurs; 1989; 12(2):103-13. PubMed ID: 2475596 [TBL] [Abstract][Full Text] [Related]